Aia Group LTD Hutchmed (China) LTD Transaction History

Aia Group LTD

$4.23 Billion
Q2 2025

A detailed history of Aia Group LTD transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Aia Group LTD holds 315,439 shares of HCM stock, worth $4.76 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

315,439

Previous 315,439 -0.0%

Holding current value

$4.76 Million

Previous $4.74 Million 0.06%

% of portfolio

0.11%

Previous 0.13%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$16.36 - $21.78 $975,694 - $1.3 Million	-59,639 Reduced 15.9%	315,439 $5.4 Million
Q1 2024 May 06, 2024	SELL	$12.08 - $18.56 $195,696 - $300,672	-16,200 Reduced 4.14%	375,078 $6.3 Million
Q3 2023 Nov 01, 2023	SELL	$11.85 - $16.95 $687,003 - $982,676	-57,975 Reduced 12.9%	391,278 $6.63 Million
Q1 2023 Apr 28, 2023	SELL	$13.02 - $19.87 $928,612 - $1.42 Million	-71,322 Reduced 13.7%	449,253 $5.85 Million
Q4 2022 Jan 31, 2023	BUY	$7.65 - $15.51 $455,251 - $923,000	59,510 Added 12.91%	520,575 $7.69 Million
Q3 2022 Nov 04, 2022	BUY	$8.63 - $15.52 $901,187 - $1.62 Million	104,425 Added 29.28%	461,065 $4.09 Million
Q1 2022 May 06, 2022	BUY	$15.52 - $35.65 $500,970 - $1.15 Million	32,279 Added 9.95%	356,640 $6.75 Million
Q3 2021 Nov 05, 2021	SELL	$35.66 - $42.94 $4.02 Million - $4.84 Million	-112,757 Reduced 25.8%	324,361 $11.9 Million
Q4 2020 Feb 12, 2021	BUY	$27.51 - $34.36 $12 Million - $15 Million	437,118 New	437,118 $15 Million
Q3 2020 Nov 16, 2020	SELL	$25.8 - $34.61 $123,840 - $166,128	-4,800 Closed	0 $0
Q1 2019 May 13, 2020	BUY	$21.27 - $30.58 $102,096 - $146,784	4,800 New	4,800 $142,000

Others Institutions Holding HCM

# of Institutions

Shares Held

6.07M

Call Options Held

Put Options Held

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.61B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aia Group LTD with notifications on news.

Account